The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M., Chun, J. J. M., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,201–1,300 of 2,162
Autoantibody potential of cancer therapeutic monoclonal antibodies
McIntyre, J. A., & Faulk, A. W. P. (2009) · International Journal of Cancer · doi:10.1002/ijc.25038 · Cited by 10
Fu, K., Cheng, Q., Liu, Z., Chen, Z., Wang, Y., Ruan, H., Zhou, L., Xiong, J., Xiao, R., Liu, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104426 · Cited by 10
“serious adverse reactions and life-threatening inflammatory responses from a ‘‘cytokine storm’’ after injection of a 1/500 dose of the anti-CD28 monoclonal antibody TGN1412, which was found to be safe in animal tests [21,22].”
BackgroundCD 28 signals the differential control of regulatory T cells and effector T cells
Mikami, N., & Sakaguchi, S. (2014) · European Journal of Immunology · doi:10.1002/eji.201444513 · Cited by 13
“Healthy volunteers treated with TGN1412/TAB08 at a much lower dose (1~7/1000), compared with the previous trial [5], scarcely produced inflammatory cytokines but produced anti-inflammatory IL-10 [8].”
BackgroundResultClinical Translation of Multipotent Mesenchymal Stromal Cells in Transplantation
Leuning, D. G., Reinders, M. E. J., de Fijter, J. W., & Rabelink, T. J. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.06.002 · Cited by 9
Harnessing the immune system for the treatment of melanoma: current status and future prospects
Guennoun, A., Sidahmed, H., Maccalli, C., Seliger, B., Marincola, F. M., & Bedognetti, D. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1176529 · Cited by 10
“formed preclinical data are necessary to drive the selection of target molecules for immunomodulating therapy [71,72].”
BackgroundBôle‐Richard, E., Gamonet, C., Certoux, J.-M., Idirène, I., Larosa, F., Deconinck, É., Mosseley, A.-M., Tiberghien, P., Borg, C., Ferrand, C., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.39 · Cited by 14
Gill, S. K., Islam, M. N., Shaw, I., Ribeiro, A., BRADLEY, B. A., Brien, T., Kilcoyne, M., Ceredig, R., & Joshi, L. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.009 · Cited by 12
A Model-Based Investigation of Cytokine Storm for T-Cell Therapy
Hopkins, B., Tucker, M., Pan, Y., Fang, N., & Huang, Z. J. (2018) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2018.09.039 · Cited by 10
Yang, X., Kang, N., Toyofuku, W. M., & Scott, M. D. (2018) · Immunobiology · doi:10.1016/j.imbio.2018.12.003 · Cited by 10
García‐Fandiño, R., & Piñeiro, Á. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610024 · Cited by 9
“They have even been observed as a result of clinical trials with monoclonal antibodies able to stimulate T cells (25, 26).”
BackgroundDirty mice join the immunologist's toolkit
Kuypers, M., Despot, T., & Mallevaey, T. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104817 · Cited by 10
Johnson, A. M., Barigye, R., & Saminathan, H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1908060 · Cited by 9
“groups of molecules such as chemokines and colony-stimulating factors (CSFs) may constitute “CSs,” which often lead to pathological and clinical manifestations.(116) Some of these effects may become life-threatening or are associated with unfavorable clinical outcomes in patients.”
BackgroundHughes, L., Carton, R., Minguzzi, S., McEntee, G., Deinum, E. E., O’Connell, M. J., & Parle‐McDermott, A. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.05.017 · Cited by 10
“Although high profile mishaps in translating from animal models to clinical trials are rare [27], it does emphasise that attention to the detail of the differences between animal models and humans is warranted.”
BackgroundHoutenbos, I., Santegoets, S. J. A. M., Westers, T. M., Waisfisz, Q., Kipriyanov, S. M., Denkers, F., Scheper, R. J., de Gruijl, T. D., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.06990.x · Cited by 10
“Recently, the unfortunate results of a phase 1 clinical trial of the superagonistic monoclonal CD28 antibody, TGN1412, drew a lot of attention (Suntharalingam et al, 2006).”
BackgroundDose-toxicity models in oncology
Adamina, M., & Joerger, M. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.543674 · Cited by 10
“Recently, a Phase I clinical trial led six healthy volunteers within hours of administration of an IND into refractory multiple organ failures [12].”
BackgroundA hearty solution for acute myeloid leukemia
Hung, Y.-J., & Liu, H. E. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.197 · Cited by 10
No Cure Yet for HIV‐1, But Therapeutic Research Presses On
Schooley, R. T., & Mellors, J. W. (2007) · The Journal of Infectious Diseases · doi:10.1086/511830 · Cited by 10
“As was recently shown with a ligand for CD28, engagement of the immune response can also have considerable downsides [15].”
BackgroundCobbold, S. P. (2009) · Immunotherapy · doi:10.2217/imt.09.9 · Cited by 11
Editor’s inaugural issue foreword: perspectives on translational and clinical research
Heger, M. (2015) · Journal of Clinical and Translational Research · doi:10.18053/jctres.201501.005 · Cited by 11
“[16] Suntharalingam G , Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N.”
BackgroundHuman Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function
Dudek, S., Weißmüller, S., Anzaghe, M., Miller, L., Sterr, S., Hoffmann, K., Hengel, H., & Waibler, Z. (2019) · European Journal of Immunology · doi:10.1002/eji.201847924 · Cited by 11
Liu, H., Yang, Y., Jiang, J., Wang, X., Zhang, C., Jiang, Y., Hong, L., & Huang, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s223697 · Cited by 10
“Our findings were similar to what had been previously reported about the hemorrhagic coagulation abnormalities in the CRS caused by immunotherapy.(22,23) However, VTE during CRS has never been reported.”
ResultRoy, N., Kashyap, J., Verma, D., Tyagi, R. K., & Prabhakar, A. (2020) · Transactions of Indian National Academy of Engineering · doi:10.1007/s41403-020-00148-0 · Cited by 10
Immunomodulators: A brave new world
Ballas, Z. K. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.1158 · Cited by 9
Combination Immunosuppressive Therapies
Robinson, M. R., Korman, B. D., & Korman, N. J. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.8.1053 · Cited by 10
Pai, R., Ma, N., Connor, A. V., Danilenko, D. M., Tarrant, J. M., Salvail, D., Wong, L., Hartley, D. P., Misner, D., Stefanich, E., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw037 · Cited by 9
Davar, D., Cavalcante, L. L., Lakhani, N. J., Moser, J. C., Millward, M., McKean, M. A., Voskoboynik, M., Sanborn, R. E., Grewal, J. S., Narayan, A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009474 · Cited by 9
CAR T cells in solid tumors and metastasis: paving the way forward
Sirini, C., Rossi, L., Moresco, M. A., & Casucci, M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10213-7 · Cited by 10
“For instance, the intravenous administration of a humanized super-agonistic CD28-specific antibody in humans triggered a CRS that was not predicted in syngeneic mouse models [167].”
Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions
Li, L., Naisbitt, D. J., Sun, Y., & Zhang, F. (2024) · Clinical & Experimental Allergy · doi:10.1111/cea.14583 · Cited by 10
Al-Naimi, M. S., Abu-Raghif, A. R., & Fawzi, H. A. (2024) · Toxicology Reports · doi:10.1016/j.toxrep.2024.101808 · Cited by 11
Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
Boehm, D. T., Landreth, K. M., Sen-Kilic, E., Lee, K. S., Misra, B., Bobbala, S. K. R., Damron, F. H., & Liu, T. W. B. (2025) · Scientific Reports · doi:10.1038/s41598-025-89930-0 · Cited by 12
Half-life extension of therapeutics: Applications and mechanisms
Pathivada, K., & Glassman, P. M. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103724 · Cited by 9
Programmed Death‐1: therapeutischer Erfolg nach über 100 Jahren Krebsimmuntherapie
Dömling, A. S. S., & Holak, T. A. (2014) · Angewandte Chemie · doi:10.1002/ange.201307906 · Cited by 9
Kerpel‐Fronius, S., Becker, S., Barrett, J., Brun, J., Carlesi, R. M., Chan, A., Collia, L. F., Dubois, D. J., Kleist, P., Koski, G., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00843 · Cited by 11
“Examples of two recent early clinical trial tragedies caused by TGN1412 (TeGenero Immuno Therapeutics AG), (Reason, 2000; Suntharalingam et al., 2006; Sims, 2009; Attarwala, 2010), and by BIA 10-2474 (Bial-Portela & Ca.”
BackgroundAnimal Models in Toxicologic Research: Rodents
Clements, P., Bolon, B. N., McInnes, E. F., Mukaratirwa, S., & Scudamore, C. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00011-x · Cited by 17
A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
Niazi, S. K. (2023) · Pharmaceuticals · doi:10.3390/ph16111556 · Cited by 13
CD80-Fc fusion protein as a potential cancer immunotherapy strategy
Wang, S., Hu, P., Fan, J., Zou, J., Hong, W., Huang, X., Pan, D., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad029 · Cited by 10
“This also suggests that FPT155 is not a CD28 agonist and does not cause a severe cytokine storm [ 50].”
BackgroundInfluentialPathology in Non-Clinical Drug Safety Assessment
Kerlin, R. L., & Li, X. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415759-0.00024-8 · Cited by 9
Applications of Translational Bioinformatics in Transplantation
Khatri, P., Sarwal, M., & Butte, A. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.120 · Cited by 9
Forme Fruste of HLH (haemophagocytic lymphohistiocytosis): diagnostic and therapeutic challenges
Inoue, S., Mangat, C., Rafee, Y., & Sharman, M. (2015) · BMJ Case Reports · doi:10.1136/bcr-2014-206190 · Cited by 9
“21 These changes are markedly similar to the characteristics of HLH, except that there was no neutropenia.”
Target Therapies in Systemic Lupus Erythematosus: Current State of the Art
Więsik–Szewczyk, E., Łacki, J. K., Feleszko, W., & Olesińska, M. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955710792007187 · Cited by 9
T Cell Co-Stimulation: Inhibition of Immunosuppression?
Sundqvist, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00974 · Cited by 9
“The immense power and lethality of T cell responses induced by certain superagonistic anti-CD28 antibodies and superantigens may also seem inconsistent with the concept that co-stimulation simply delivers an immunostimulatory signal (13, 14).”
BackgroundLegacy of the influenza pandemic 1918: The host T cell response
McMichael, A. J. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.08.003 · Cited by 9
A Model-Based Investigation of Cytokine Dynamics in Immunotherapies
Hopkins, B., Pan, Y., Tucker, M., & Huang, Z. J. (2018) · Processes · doi:10.3390/pr7010012 · Cited by 10
“, +/−50%), the v iability s own in cytokine peak values is compar ble to the values shown in TGN1412 clinical data [7].”
BackgroundMethodResultInfluentialBiologics in dermatology: Off-label indications
Chopra, A., Mitra, D., Saraswat, N., Mitra, B., Talukdar, K., & Agarwal, R. (2020) · Indian Dermatology Online Journal · doi:10.4103/idoj.idoj_407_18 · Cited by 10
“These outlined the clinical picture of a CRS.[103,104] Such reactions were also documented for infliximab, rituximab, and alemtuzumab.”
BackgroundAre all cytokine storms the same?
Panoskaltsis, N. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02822-2 · Cited by 11
“IL-10 seems to be crucial for tempering CRS and supplementation of this cytokine to restore balance may be a preferable option to blocking pro-inflammatory cytokines (IL-6, TNFα or IL-1β), which could exacerbate infectious pathology [1, 13].”
BackgroundResultInfluentialSelf-citationSo Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research
Kleinman, A. J., Pandrea, I., & Apetrei, C. (2022) · Viruses · doi:10.3390/v14010135 · Cited by 11
Long, M., Mims, A. S., & Li, Z. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2131569 · Cited by 10
“a dangerous cytokine storm as learned from the disastrous TGN1412 trial (Suntharalingam et al. 2006).”
BackgroundInfluentialLost in Translation ( LiT ): IUPHAR Review 6
Dollery, C. T. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12580 · Cited by 11
“The effect of the superagonist TGN1412 on the CD28 receptor of T-cells caused a near catastrophe in a group of healthy volunteers due to the intensity of the cytokine release reaction (Suntharalingam et al., 2006 , Eastwood et al., 2010 .”
BackgroundZadeh-Khorasani, M., Nolte, T., Mueller, T. D., Pechlivanis, M., Ruëff, F., Wollenberg, A., Fricker, G., Wolf, E., Siebeck, M., & Gropp, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-4 · Cited by 9
“; licensee BioMe Creative Commons Attribution License (http:/ distribution, and reproduction in any medium 1412 [1] which tragically triggered a cytokine storm in healthy volunteers despite being well tolerated in cynomolgus monkeys.”
BackgroundTargeting CD28 to prevent transplant rejection
Yeung, M. Y., Najafian, N., & Sayegh, M. H. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.863875 · Cited by 10
“Tragically, an unexpected and severe cytokine storm leading to end-organ damage developed in all six individuals [130].”
BackgroundAn Overview of the Field of Peptide and Protein Delivery
van der Walle, C. F., & Olejnik, O. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-384935-9.10001-x · Cited by 14
Tim-3: Biomarqueur et cible thérapeutique en cancérologie
Granier, C., Gey, A., Dariane, C., Méjean, A., Timsit, M., Blanc, C., Verkarre, V., Radulescu, C., Fabre, E., Vano, Y. A., et al. (2018) · médecine/sciences · doi:10.1051/medsci/20183403011 · Cited by 16
“Elle présente une capacité activatrice importante, puisque l’administration d’anticorps agoniste ciblant cette molécule chez l’homme entraîne une libération massive de cytokines conduisant à des défaillances multi-organes [2].”
BackgroundUlrich, P. C., Blaich, G., Baumann, A., Fagg, R., Hey, A., Kießling, A., Kronenberg, S., Lindecrona, R. H., Mohl, S., Richter, W., et al. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.01.013 · Cited by 9
French Phase I clinical trial disaster: Issues, learning points, and potential safety measures
Gupta, Y., Singh, H., & Sarangi, S. (2018) · Journal of Natural Science Biology and Medicine · doi:10.4103/jnsbm.jnsbm_181_17 · Cited by 9
The HPS2-THRIVE Collaborative Group, Haynes, R., Chen, F., Wincott, E., Dayanandan, R., Lay, M., Parish, S., Bowman, L. J., Landray, M., & Armitage, J. (2019) · Trials · doi:10.1186/s13063-019-3779-4 · Cited by 9
“Although many were aware of the TGN1412 episode at Northwick Park where many participants became severely ill [8], most realised that HPS2-THRIVE was a different type of trial and were reassured by the monitoring (although some were concerned that the clinics were run by a nurse rather than a doctor).”
BackgroundTakabatake, Y., Li, X., Mizui, M., Miyasato, K., Matsui, I., Kawada, N., Imai, E., Hünig, T., Takahara, S., Wada, T., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00229 · Cited by 9
“During our animal experiment, on March 13, 2006, humanized CD28-SA (TGN1412) was administered to six healthy volunteers in London as a phase I clinical trial and caused severe and lifethreatening adverse effects owing to the cytokine storm (33,34).”
MethodMolecular Insights into γδ T Cell Costimulation by an Anti-JAML Antibody
Verdino, P., Witherden, D. A., Ferguson, M. S., Corper, A. L., Schiefner, A., Havran, W. L., & Wilson, I. A. (2011) · Structure · doi:10.1016/j.str.2010.10.007 · Cited by 11
“The dependency of HL4E10 activity on primary TCR-CD3 signals without interfering with the natural JAMLCAR interaction might help avoid the adverse effects elicited by anti-CD28 superagonistic Abs in clinical trials (Suntharalingam et al., 2006; Waibler et al., 2008).”
Anti-inflammatory therapies in bronchiectasis
Smith, D. J., Chang, A. B., & Bell, S. C. (2011) · European Respiratory Society eBooks · doi:10.1183/1025448x.100004510 · Cited by 9
Molecular Determinants of Inverse Agonist Activity of Biologicals Targeting CTLA-4
Teft, W. A., & Madrenas, J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3631 · Cited by 9
Wise, M. P., Gallimore, A., & Godkin, A. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmc062767 · Cited by 9
Adjuvants for Protein‐ and Carbohydrate‐Based Vaccines
Guy, B. (2008) · Wiley eBooks · doi:10.1002/9780470473283.ch3 · Cited by 9
Watkins, S. L. (2023) · Membranes · doi:10.3390/membranes13020148 · Cited by 9
“This occurred again for anti-CD28 and others until the overall structural effects of antibodies began to be incorporated into the process [110].”
BackgroundSingh, S., Kachhawaha, K., & Singh, S. K. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116303 · Cited by 12
The estimation and translation uncertainties in applying NOAEL to clinical dose escalation
Chen, C., Lavezzi, S. M., & McDougall, D. (2024) · Clinical and Translational Science · doi:10.1111/cts.13831 · Cited by 7
Innovative therapeutic strategies to overcome radioresistance in breast cancer
Arnold, C. R., Mangesius, J., Portnaia, I., Ganswindt, U., & Wolff, H. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1379986 · Cited by 8
Exploiting host kinases to combat dengue virus infection and disease
Bourgeois, N. M., Wei, L., Kaushansky, A., & Aitchison, J. D. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106172 · Cited by 10
You, S., & Chatenoud, L. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283402bd8 · Cited by 8
Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention
Zhang, B., Li, X., Yin, T., Qin, D., Chen, Y., Ma, Q., Shu, P., & Wang, Y. (2022) · Journal of Oncology · doi:10.1155/2022/4259205 · Cited by 12
The Serum ACE2, CTSL, AngII, and TNFα Levels after COVID-19 and mRNA Vaccines: The Molecular Basis
Pencheva, M. M., Bozhkova, M., Kalchev, Y., Petrov, S., Baldzhieva, A., Kalfova, T., Dichev, V., Keskinova, D., Genova, S., Atanasova, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123160 · Cited by 9
“…cells (monocytes, macrophages, neutrophiles, dendritic cell (DC), and natural killer cells (NK cells)) and activate cells, belonging to the adaptive immunity (CD4+ and CD8+ T lymphocytes) from nearby tissues, which can secrete IL-2, IFN-γ and TNF α , leading to an acceleration of the damage [18].”
BackgroundAnalysis of cytokine release assay data using machine learning approaches
Xiong, F., Janko, M., Walker, M., Makropoulos, D., Weinstock, D., Kam, M., & Hrebien, L. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.024 · Cited by 9
“The analysis of TGN 1412 treated patients shows that TNF-α was increased at 1 h after infusion and IFN-γ, IL-2, IL-6 and IL-10were increased after 4 h [44].”
MethodCzerwiński, M., Kazmi, F., Parkinson, A., & Buckley, D. B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060186 · Cited by 8
Schneider, C. K., & Kalinke, U. (2007) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-007-0331-6 · Cited by 8
Application of Modeling and Simulation in the Development of Protein Drugs
Roskos, L. K., Ren, S., & Robbie, G. J. (2010) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4419-7415-0_17 · Cited by 8
“Segel (1993) , Gibiansky (2008), kon*C*R� (koff + kint) and Yan et al .( 2010)”
ILC2: There’s a New Cell in Town
Wang, Y. M., Bakhtiar, M., & Alexander, S. I. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040398 · Cited by 8
Spicer, P., & Runkel, L. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1557146 · Cited by 8
“The low-dose and slow infusion time was selected as a result of an unfortunate ‘trial and error’ Phase I study, sponsored by TeGenero, in which theralizumab (then known as TGN1412) ended with catastrophic multi-organ failure in six healthy volunteers [6].”
BackgroundMonteiro, M. F., Papaserafeim, M., Réal, A., Yung, G. P., & Seebach, J. D. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ma0620-039r · Cited by 9
Mascolo, S., Carleo, M. A., Contieri, M., Izzo, S., Perna, A., Luca, A. D., & Esposito, V. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26651 · Cited by 7
“These aspects are the typical clinical features of four syndromes: macrophage activation syndrome (MAS), catastrophic antiphospholipid syndrome (cAPS),(43) septic shock and adverse reaction to the biological anti‐CD‐28 compound.(44) IL‐6 plays a fundamental role in the activation of immune re-”
BackgroundSpiesberger, K., Paulfranz, F., Egger, A., Reiser, J., Vogl, C., Rudolf-Scholik, J., Mayrhofer, C., Große‐Hovest, L., & Brem, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140471 · Cited by 10
“Since the detrimental outcome of a clinical study from 2006 in which the application of a superagonist anti-CD28 monoclonal antibody (TGN1412) caused severe inflammatory responses [17], heightened awareness is still paid to antibodies harboring CD28 binding sites.”
BackgroundCoenen, M., Hinze, A. V., Mengel, M., Fuhrmann, C., Lüdenbach, B., Zimmermann, J., Dykstra, V., Fimmers, R., Viviani, R., Stingl, J., et al. (2015) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-015-0025-x · Cited by 6
“[17].”
Ethical issues in rheumatology clinical trials
Sugarman, J., & Bingham, C. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0829 · Cited by 8
Biologics in the Pipeline: Large Molecules With High Hopes or Bigger Risks?
Zhou, H. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006297230 · Cited by 8
“Even though the selected FIH dose was only 1/500th of the reported safe animal dose,(2,3) all 6 volunteers experienced an acute, immunemediated cytokine storm that unfortunately led to multiorgan failure.(4) The Medicines and Healthcare Products Regulatory Agency (MHRA), in conjunction with the German Regulatory Autho…”
BackgroundKawaguchi, A. T., Kametani, Y., Kato, S., Furuya, H., Tamaoki, K., & Habu, S. (2009) · Artificial Organs · doi:10.1111/j.1525-1594.2008.00703.x · Cited by 8
Characterization of a New Mouse Model for Peripheral T Cell Lymphoma in Humans
Beyersdorf, N., Werner, S., Wolf, N., Herrmann, T., & Kerkau, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028546 · Cited by 8
“Pre-cautions [7,8], however, need to be taken when targeting either the TCR complex or CD28 with monoclonal antibodies in humans as a profound activation of normal T cells may induce a toxic ‘cytokine storm’ [9,10].”
Kamperschroer, C., Kaur, A., & Lebrec, H. N. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.631610 · Cited by 8
“, cytokine-driven adverse events) (Suntharalingam et al., 2006).”
Burkhart, P. W. M. K. K. (2014) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000195 · Cited by 8
Beyersdorf, N., Werner, S., Wolf, N., Hünig, T., & Kerkau, T. (2015) · European Journal of Immunology · doi:10.1002/eji.201445317 · Cited by 8
Hazard Identification and Risk Assessment for Biologics Targeting the Immune System
Weir, A. B. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897409 · Cited by 8
New immunosuppressants in pediatric solid organ transplantation
Marks, S. D. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32835741cd · Cited by 8
“This was borne out when a Phase I trial of TGN1412, a model superagonist anti-CD28 monoclonal antibody caused a severe cytokine storm resulting in a systemic inflammatory response syndrome requiring admission to intensive care for six healthy adult young male volunteers [18].”
BackgroundThe Science and Business of Drug Discovery: Demystifying the Jargon
Zanders, E. D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9902-3 · Cited by 9
Hasezaki, T., Yoshima, T., Mattsson, M., et al. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz103 · Cited by 8
Luvanda, M. K., Posch, W., Noureen, A., Lafon, E., Zaderer, V., Lass‐Flörl, C., & Wilflingseder, D. (2021) · Journal of Fungi · doi:10.3390/jof7030221 · Cited by 10
“The generation of more human-like in vitro models incorporating complex parameters, such as primary cells and extensive vasculature, is imperative during preliminary drug screening studies so as to avoid situations where animal experimental outcomes do not translate reliably, such as in the TGN1412 trial disaster of 2…”
BackgroundMyers, L. P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8549-4_2 · Cited by 8
T cells stimulatedin vitrohave a suppressive function but do not contain only regulatory T cells
Valencic, E., Piscianz, E., Tommasini, A., & Granzotto, M. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03502.x · Cited by 9
Mouse Medicine and Human Biology
Young, N. S. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.03.024 · Cited by 8
Müller, D., & Kontermann, R. E. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch11 · Cited by 9
Structured Risk Assessment for First-in-Human Studies
van Iersel, M. T., Greenberg, H. E., & Westrick, M. L. (2017) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479017705156 · Cited by 7
“In 2006 a first-in-human (FiH) study with a CD28-specific monoclonal antibody (TGN 1412) conducted at a Clinical Pharmacology Unit (CPU) in London, in the UK derailed in a life-threatening “cytokine storm” in all six healthy subjects receiving the starting dose.(1) Ten years later, in an FiH study with a small-molecul…”
BackgroundAl-Mansoori, L., AlQahtani, A. D., Elsinga, P. H., & Goda, S. K. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211057371 · Cited by 7
“25,26 This provides a good reason to test such new compounds safety before moving to clinical trials.”
BackgroundZheng, R., Guan, T., Hong, C., Yao, Y., Fang, Y., Huang, W., Chen, C., Zeng, H., Huang, J., Lin, H., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05542-8 · Cited by 8
“However, in a phase I trial, TGN1412 resulted in horrific side-effects in six volunteers due to cytokine release storm [18].”
BackgroundWang, X., Liu, Q., Cheng, P., Yang, T., Zhao, T., Liu, M., Dai, E., Sha, W., Yuan, J., Rong, J., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156527 · Cited by 8
Elsayed, A., Pellegrino, C. E., Plüss, L., Peissert, F., Benz, R., Ulrich, F., Thorhallsdottir, G., Plaza, S. D., Villa, A., Mock, J., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2220839 · Cited by 9
“Inspired by the crucial role of CD28, the TeGenero trial in 2006 using a CD28-activating mAb (TGN1412) was initiated, but it resulted in a clinical tragedy in which all six healthy volunteers who received the drug developed CRS with severe life-threatening complications.(33) This incident halted further development of…”
BackgroundMethodInfluential
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.